ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.59 -0.60%

-$0.13 today

Market cap
$3.04B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.45M

Average 1.66M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$109.84M

FY 2025 · Annual

-30.4% YoY

Investing Cash Flow

-$302.56M

FY 2025 · Annual

Financing Cash Flow

$49.88M

FY 2025 · Annual

+628.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
Deferred Income Tax0000(249.88M)
Stock-Based Compensation63.62M68.2M66.42M67.05M0
Change in Working Capital(24.82M)37.99M18.13M4.16M(89.76M)
Accounts Receivables(16.12M)2.26M(39.27M)(2.35M)(43.54M)
Inventory(4.21M)2.42M(28.81M)(49.55M)(18.2M)
Accounts Payables(1.62M)5.87M4.8M(1.35M)(5.29M)
Other Working Capital(2.88M)27.44M81.41M57.4M(22.73M)
Other Non-Cash Items75K(6.28M)(12.12M)(155.82M)46.71M
Operating Cash Flow(125.66M)(114.04M)16.7M157.72M109.84M
Capital Expenditures(1.12M)0(40.05M)(523K)(4.69M)
Acquisitions (Net)69.98M0(32.05M)00
Purchases of Investments(492.8M)(363.17M)(369.99M)(505.1M)(692.57M)
Sales of Investments422.82M436.42M442.03M328.57M493.53M
Other Investing Activities(69.98M)032.05M146.52M0
Investing Cash Flow(71.1M)73.24M32M(30.54M)(302.56M)
Debt Repayment00000
Common Stock Issued18.16M8.2M25.13M6.85M49.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow18.16M8.2M25.13M6.85M49.88M
Effect of Forex Changes7K6K(18K)(94K)951K
Net Change in Cash(178.59M)(32.59M)73.81M133.93M(141.89M)
Free Cash Flow(126.78M)(114.04M)(23.35M)157.2M105.15M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$391.0M
+ D&A$11.8M
+ Stock-Based Comp$0
- Deferred Tax-$249.9M
- Working Capital-$89.8M
+ Other Non-Cash$46.7M
= Operating Cash Flow$109.8M
- Capex-$4.7M
= Free Cash Flow$105.1M

Analysis

FY2025 free cash flow is $105.1M. FCF conversion is 26.9% of net income. Operating cash flow was $109.8M, with capex of -$4.7M. The largest bridge item is Deferred Tax at -$249.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
8-KCurrent reportOct 23, 2026

Does ACAD generate free cash flow?

ACADIA Pharmaceuticals Inc. (ACAD) generated $105.15M of free cash flow in fiscal 2025.

How much operating cash flow does ACAD produce?

Operating cash flow was $109.84M, before capital expenditures of $4.69M.